Trakcel integrates cell therapy thawing tech in deal with Biocision
The agreement – financial terms of which were not disclosed – will see Cardiff, Wales-based Trakcel integrate Biocision’s recently expanded range of Thawstar point-of-care thawing technologies into its service offering.
Trakcel’s technology is a paperless system designed to precisely track and monitor cell therapies from manufacturing site to clinic. The idea is to provide an automated way of keeping track of all parties involved in transport, storage and distribution of cell therapies.
Precise control is particularly import for cell thawing according to Trakcel CTO Jon Curley.
He said: “The importance of automation and standardization of the thawing process for cell therapies remain under-appreciated for frozen cell therapeutics.
“BioCision’s technology brings reproducibility and reliability into that process and this partnership better positions our cell therapy customers to achieve excellence in cold chain management.”
This was echoed by Biocision spokesman Samuel Kent, who said integrating the Thawstar platform into Trakcel’s Connected Service programme will offer “a real-time window into a crucial stage of the cell therapy handling process.
He added that: “By including tracking information such as temperature recording and vial identification, we enable critical de-risking checks like patient-therapy matching in early pre-clinical development through to point-of care.”